SGMO

0.6223

4.73% -0.0309

Pre-mercato: .75 0.1277 +20.52%

Sangamo Therapeutics Inc (SGMO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$0.6532

Aprire:

$0.61

Volume 24 ore:

15.09M

Relative Volume:

2.42

Capitalizzazione di mercato:

$139.84M

Reddito:

$52.29M

Utile/perdita netta:

$-134.84M

Rapporto P/E:

-0.8297

EPS:

-0.75

Flusso di cassa netto:

$-117.11M

1 W Prestazione:

-27.41%

1M Prestazione:

-32.40%

6M Prestazione:

-21.48%

1 anno Prestazione:

+2.02%

Intervallo 1D:

$0.5779

$0.639

Intervallo di 1 settimana:

$0.5463

$0.8542

Portata 52W:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Nome

Sangamo Therapeutics Inc

Settore

Healthcare (1163)

Industria

Biotechnology (678)

Telefono

(510) 970-6000

Indirizzo

501 CANAL BLVD., RICHMOND, CA

Dipendente

183

Cinguettio

@sangamotx

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

SGMO's Discussions on Twitter

Confronta SGMO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SGMO Sangamo Therapeutics Inc	0.6223	139.84M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	66.76B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-13	Aggiornamento	Truist	Hold → Buy
2024-12-10	Reiterato	H.C. Wainwright	Buy
2023-11-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Downgrade	BofA Securities	Neutral → Underperform
2023-02-27	Aggiornamento	Wedbush	Neutral → Outperform
2023-01-06	Downgrade	BofA Securities	Buy → Neutral
2022-06-13	Ripresa	Wedbush	Neutral
2021-05-04	Iniziato	RBC Capital Mkts	Outperform
2021-01-07	Ripresa	Guggenheim	Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-12-16	Ripresa	H.C. Wainwright	Buy
2020-09-08	Iniziato	BofA Securities	Buy
2020-07-07	Iniziato	SunTrust	Buy
2019-08-26	Iniziato	H.C. Wainwright	Buy
2018-11-14	Downgrade	JP Morgan	Overweight → Neutral
2018-11-09	Downgrade	Guggenheim	Buy → Neutral
2018-10-10	Iniziato	Guggenheim	Buy
2018-06-20	Iniziato	BofA/Merrill	Buy
2017-11-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-06-22	Ripresa	Jefferies	Buy
2016-11-01	Downgrade	Wedbush	Outperform → Neutral
2016-10-19	Downgrade	Piper Jaffray	Overweight → Neutral
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-10-23	Ripresa	Jefferies	Buy
2013-05-03	Iniziato	BioLogic Equity Research	Sell
2011-02-23	Reiterato	JMP Securities	Mkt Outperform
2010-07-29	Reiterato	Wedbush	Outperform
2009-10-19	Iniziato	Brean Murray	Sell
2009-10-07	Reiterato	Leerink Swann	Outperform
2009-08-25	Reiterato	JMP Securities	Mkt Outperform

Mostra tutto

Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie

05:20 AM

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

05:20 AM

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com India

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire

Apr 03, 2025

Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025

Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025